Point72 Asset Management L.P. purchased a new position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 26,828 shares of the specialty pharmaceutical company's stock, valued at approximately $970,000.
A number of other hedge funds and other institutional investors have also made changes to their positions in SUPN. ProShare Advisors LLC lifted its holdings in Supernus Pharmaceuticals by 29.0% in the fourth quarter. ProShare Advisors LLC now owns 17,839 shares of the specialty pharmaceutical company's stock valued at $645,000 after acquiring an additional 4,008 shares during the last quarter. Quantinno Capital Management LP lifted its stake in shares of Supernus Pharmaceuticals by 11.5% in the 4th quarter. Quantinno Capital Management LP now owns 8,401 shares of the specialty pharmaceutical company's stock valued at $304,000 after purchasing an additional 864 shares during the last quarter. Nuveen Asset Management LLC lifted its stake in shares of Supernus Pharmaceuticals by 0.7% in the 4th quarter. Nuveen Asset Management LLC now owns 134,127 shares of the specialty pharmaceutical company's stock valued at $4,850,000 after purchasing an additional 903 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of Supernus Pharmaceuticals by 3.9% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 28,563 shares of the specialty pharmaceutical company's stock worth $1,033,000 after purchasing an additional 1,083 shares during the period. Finally, Jefferies Financial Group Inc. acquired a new stake in shares of Supernus Pharmaceuticals during the 4th quarter worth about $890,000.
Wall Street Analysts Forecast Growth
A number of research analysts have commented on SUPN shares. StockNews.com raised shares of Supernus Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Friday, May 16th. Cantor Fitzgerald reissued a "neutral" rating and issued a $36.00 price target on shares of Supernus Pharmaceuticals in a research note on Wednesday, February 26th.
Get Our Latest Research Report on SUPN
Insider Activity at Supernus Pharmaceuticals
In related news, SVP Jonathan Rubin sold 927 shares of the firm's stock in a transaction dated Friday, February 21st. The stock was sold at an average price of $39.15, for a total transaction of $36,292.05. Following the completion of the transaction, the senior vice president now directly owns 7,853 shares in the company, valued at $307,444.95. This trade represents a 10.56% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Company insiders own 8.80% of the company's stock.
Supernus Pharmaceuticals Stock Down 1.7%
SUPN opened at $32.63 on Thursday. Supernus Pharmaceuticals, Inc. has a 52 week low of $25.53 and a 52 week high of $40.28. The business has a fifty day simple moving average of $31.98 and a 200-day simple moving average of $34.80. The firm has a market cap of $1.83 billion, a P/E ratio of 30.50 and a beta of 0.74.
Supernus Pharmaceuticals Company Profile
(
Free Report)
Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.
See Also
Want to see what other hedge funds are holding SUPN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Supernus Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Supernus Pharmaceuticals wasn't on the list.
While Supernus Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
